271
KLINICKÁ341804301074588109168189242288347
FARMAKOLOGIE708804301074392139212266313373416475534555599
A13288043010753
FARMACIE1402804301074292139211266317337381
/18048043010757
Klin1880804301077091109157
Farmakol2057804301074278105179220258305325
Farm2402804301074178104179
2019;2601804301074386126164180
33(3):2801804301074385107150171185
29–363006804301074487135175219
/32448043010757
www.klinickafarmakologie.cz4568804301076513320121425327329234035839843647950254457164568672477179183988990895196610061045
361838026012657114
HLAVNÍ341207012670127198263336370
TÉMA733207012657114204274
Bezpečnost34136501063466101135167202243284317349
léčby7053650106306297133169
roztroušené89036501063374105139175216257289321362394
sklerózy12993650106316698130166207238277
z1591365010631
dlouhodobého163836501063769108149190231271312348380422462
hlediska211636501063970102142160192227269
ve240136501063668
vztahu248536501063669103140181221
k2722365010634
teriflunomidu27703650106316399117147179218260300354372411452
a3238365010638
alemtuzumabu329136501063869102156188229261302356396432473
19.343548085366881
Coles437549083407692127153
AJ,603549083416779
Compston6955490834076134173200222259297
DAC,10055490834584123136
Selmaj1154549083326782139171187
KW,13535490833595104
et14705490833456
al.1539549083314659
Alemtuzumab1611549083415690148169207236274331363402
vs.343649083315871
Interferon430649083124971104125146180201238276
beta‑1a719649083387395128150180208
in9426490831250
early1005649083336586101133
multiple11506490835795110132147185201236
sclerosis.1398649083265873108129165192206232246
N165664908345
Engl17136490833370109124
J185264908321
Med18866490835489128
2008;3437490833468104140152
359:5107490833567100113
1786–1801.638749083346497132170201232268299309
20.343848085367287
Cohen4468490834077115150189
JA,650849083266580
Coles746849083407793128155
AJ,918849083416880
Arnold10158490834162101139155194
DL,1225849083467892
et13348490833356
al.1405849083334962
Alemtuzumab1484849083405691149170208238276334366405
versus1905849083336788343949083266389
interferon447949083125071105126147181202239277
beta737949083387395128
1a8789490833462
as9529490833258
first‑line102394908317345481104124140155193227
treatment1265949083194174106128185220258279
for1559949083165375
patients1646949083397293108143180202229
with1888949083506688126
relapsing‑remitting3431049083215470102141167182219258280302336393408430455470507546
multiple90210490835794109131146185201235
sclerosis:11501049083265873108129166192207233245
a1408104908331
randomised14551049083185088127165223238263298337
controlled1805104908331681061271481853431149083153065104
phase46311490833877109136171
3649114908334
trial.698114908322445991107119
Lancet83311490833165103135168191
2012;103911490833468100130142
380:119711490833468104117
1819–1828.13291149083346597127165196227260294307
21.3431248085367082
Coles4391249083407793128154
AJ,6081249083416880
Twyman70212490833380114172205243
CL,9591249083407185
Arnold105812490834162101139155194
DL,12661249083467891
et137212490833456
al.14421249083324760
Alemtuzumab15161249083415792150171209238277335367406
for19371249083185577
patients3431349083397293109143181203231
with5901349083516689127
relapsing7321349083225672104143170185222262
multiple101013490835795110133148187203238
sclerosis12631349083276075110131168195210236
after15141349083335277111132
disease‑modifying166213490833954801151471732082312903283431449083385372107123161200
therapy:5581449083216095116149188219233
a806144908332
randomised8531449083215492131169227242268303343
controlled121114490833268107128150187203218253292
phase151914490833877109136171
31705144908334
trial.1754144908322435991106119
Lancet1889144908331641023431549083316587
2012;44615490833468100129142
380:60315490833469104117
1829–1839.7351549083356699133171202233267300311
22.2141548085356983
ColesAJ,CohenJA,FoxEJ,etal.CARE‑MS223254908339738711914419221722727430834437741244448149353356859663666067071273277178479584388291694796610191049
IIandCAMMS03409329454908310236298134182221274326356389419452485518
Investigators.AlemtuzumabCARE‑MS21416490831551801121371581722082392592933133383504004144475025225585856216777077447938348688999199731004
II5‑year315864908311246888118150180199
follow‑up:Efficacy33716490831449637711316218221925626630832434235938942021417490833163
and22177490833268106
safety2335749083275876109130162
findings.2510749083173370108121158195220232
Neurology27557490834578115134170185221260290
2017;3058749083346797125133
89:3204749083346779
1117–1126.3295749083346187115146175202230262274
23.2141848085367287
Willis2244849083577489104119145
MD,240584908354100111
Harding2532849083447697136151189228
KE,2775849083357083
Pickersgill2874849083354981111145167194233248263278
TP,3168849083337074
et32588490833456
al.3330849083324760
Alemtuzumab3406849083415691149171209238276334366406
for2141949083185678
Multiple22349490835492108130145184200235
Sclerosis.2484949083336580115137174200215241255
Mult27549490835593108130
Scler2900949083326480115136
2016;30519490833468100131144
22:3210949083346981
1215–1223.3307949083346495125162192222257292304
24.21411048085367186
Cohen224110490834077115150189
JA,24451049083236377
Barkhof25371049083356889120159197216
F,276810490833238
Comi282110490833976135150
G,298510490834457
et305710490833456
al.31271049083324860
Oral320210490834769102117
fingolimod33331049083173472111149165180238276316
or366310490833759
intramuscular37371049083145221411149083214275132169195226263278310331
interferon24871149083124970103124145179200236274
for27761149083165374
relapsing2865114908318516698137163177215253
multiple313011490835794109131146184200234
sclerosis.33771149083255772106127164190204230243
N3632114908345
Engl368911490833269108123
J2141124908324
Med218012490835590130
2010;232512490833468100131144
362:248512490833468102114
402–415.261412490833570103138174205235247
25.21411348085367287
Buonomo224313490833977115153192250288
AR,25501349083417790
Zappulo265913490833871110149188203241
E,291513490833649
Viceconte29801349083385587120153190229250284
G,328213490834457
et335513490833759
al.34291349083355164
Risk35081349083395480110
of363713490833756
opportunistic37121349083377621411449083397799123161199214240263278310
infections24661449083125068103135159174212250277
in275814490831250
patients28201449083397293109143181202230
treated30651449083194174106128161201
with32781449083516689127
alemtuzumab34171449083324782140161199228266324356395
for21411549083185577
multiple223015490835795110132147185201235
sclerosis.24781549083265873107128165192206232245
Expert273615490833264104139160184
Opin293315490834686101138
Drug308415490834566104143
Saf32401549083326483
2018;33361549083346799129141
17:34901549083346373
709–717.357515490833467102139170202231237
26.3939548085367187
Costelloe40395490834077104127160176191229265
L,43175490833145
Jones4377549083226099134161
J,45535490832234
Coles4600549083407793127154
A.47675490834156
Secondary48365490833267100137175214247268302
autoimmune5151549083326992129144202260297335370
diseases553454908338533939649083266193120155181
following413664908319577388126177193231270
alemtuzumab4421649083334883141163201230268326358397
therapy4834649083236196117150189220
for5070649083195779
multiple51656490835795110133148187203238
sclerosis.5418649083286075110131168393974908326416781
Expert40357490833365105140161186
Rev42367490833671103
Neurother43547490834580118139176198236271292
2012;46627490833468100130142
12:4819749083356577
335–341.49117490833568100137169205235244
27.3939848085356874
ColesAJ,CohenJA,FoxEJ,etal.CARE‑MS402384908339738712014419321822727531034637841444648349553657159963966467471673677678980084888892195297110241054
IIandCAMMS03409509184908310236398135183223275327358390421454487520
Investigators.AlemtuzumabCARE‑MS39399490831551801121371581722082392592933133383504004144475025225585856216777077447938348688999199731004
II5‑year495694908311246888118150180199
follow‑up:Efficacy516994908314496377113162182219256266308324342359389420393910490833163
and401510490833268106
safety41331049083275876109130162
findings.43081049083173370108121158195220232
Neurology455310490834578115134170185221260290
2017;48561049083346797125133
89:50021049083346779
1117–1126.50931049083346187115146175202230262274
28.39391148085367389
TOPAZ:404411490833683120158198212
1.427211490833848
Coles43391149083407794130157
AJ,45151149083416982
et461311490833760
al.46891149083345164
ACTRIMS‑ECTRIMS477211490834181117155172227261284319360396434451506540
2017,532811490833772105135141
Poster54851149083387610339391249083225678
P1188;40311249083356897128164177
2.422312490833447
Singer42841249083334887126162184
BV,44821249083357282
et457812490833457
al.46491249083324862
ACTRIMS‑ECTRIMS472512490834181117155171227260283318359395433449505539
2017,527812490833469101131138
Poster543012490833572100124158180
P736;393913490833569104139152
3.410713490834053
Traboulsee41761349083385689129169208224250286322
A,451413490834761
et459113490834063
al.46701349083375366
AAN475213490834790136
2017,490413490834075107137143
P2.50631349083417589
104;516813490833971108121
4.530513490833952
Clinicaltrials.gov.537313490834561771161311641982143939144908321435991106132146185223255265
https://42171449083375983123149162189209
clinicaltrials.gov/ct2/show/NCT02255656.4440144908331466199114146179195217239254286302328342380418450474502527562589613651689740764809850885919952987102210541088112211561170
Accessed393915490834173105139167194230270
September422515490833369109131166224264301323
7,456415490833441
2017.462115490833569102132139